Safety and efficacy of gout treatments in people with renal impairment

Abstract

Gout is common in people with chronic kidney disease and in general is sub-optimally managed. Lack of evidence due to the exclusion of people with chronic kidney disease from the majority of clinical trials, concerns about adverse effects and conflicting gout management guidelines all contribute to suboptimal management. Herein we review the evidence for the pharmacological treatment of gout, both flares and long-term urate-lowering, in people with concomitant chronic kidney disease.

Keywords

Gout / chronic kidney disease / urate-lowering therapy / NSAIDs / colchicine / corticosteroids

References

[1] Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021; 17: 633-41.

[2] Jaffe DH, Klein AB, Benis A, Flores NM, Gabay H, Morlock R, et al. Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatol. 2019; 3: 11.

[3] Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012; 7: e50046.

[4] Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125: 679-87.e1.

[5] Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015; 17: 90.

[6] Siu Y, Leung K, Tong MK, Kwan T. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006; 47: 51-9.

[7] Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005; 67: 237-47.

[8] Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al.; CKD-FIX Study Investigators. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020; 382: 2504-13.

[9] Linnane JW, Burry AF, Emmerson BT. Urate deposits in the renal medulla. Prevalence and associations. Nephron. 1981; 29: 216-22.

[10] Simmons KE, Nair HR, Phadke M, Motamedinia P, Singh D, Montgomery TA, et al. Risk Factors for Common Kidney Stones Are Correlated with Kidney Function Independent of Stone Composition. Am J Nephrol. 2023; 54: 329-36.

[11] Bao D, Lv N, Duan X, Zhang X, Wang J, Wang S, et al. Prevalence and clinical association of hyperechoic crystal deposits on ultrasonography in patients with chronic kidney disease: a cross-sectional study from a single center. J Nephrol. 2023; 36: 2467-75.

[12] Sellmayr M, Petzsche MRH, Ma Q, Krüger N, Liapis H, Brink A, et al. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease. J Am Soc Nephrol. 2020; 31: 2773-92.

[13] Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum. 1965; 8: 694-706.

[14] Leask MP, Sumpter NA, Lupi AS, Vazquez AI, Reynolds RJ, Mount DB, et al. The Shared Genetic Basis of Hyperuricemia, Gout, and Kidney Function. Semin Nephrol. 2020; 40: 586-99.

[15] Narang RK, Gamble G, Phipps-Green AJ, Topless R, Cadzow M, Stamp LK, et al. Do Serum Urate-associated Genetic Variants Influence Gout Risk in People Taking Diuretics? Analysis of the UK Biobank. J Rheumatol. 2020; 47: 1704-11.

[16] FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020; 72: 744-60.

[17] Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76: 29-42.

[18] Pisaniello HL, Fisher MC, Farquhar H, Vargas-Santos AB, Hill CL, Stamp LK, et al. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. Arthritis Res Ther. 2021; 23: 130.

[19] Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010; 62: 1060-8.

[20] Bausson J, Keller N, Hunolstein JV, Sacrez M, Michel B, Gourieux B, et al. Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease. RMD Open. 2024; 10: e003872.

[21] Stamp L, Horne A, Mihov B, Drake J, Haslett J, Chapman PT, et al. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann Rheum Dis. 2023; 82: 1626-34.

[22] Kim HW, Joo YS, Yun H, Kim JY, Jhee JH, Roh YH, et al. Colchicine use and the risk of CKD progression: a multicentre nested case-control study. Rheumatology (Oxford). 2022; 61: 4314-23.

[23] Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014; 34: 845-55.

[24] Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011; 63: 2226-37.

[25] Full prescibing information: contents* [Internet]. U.S. Food & Drug Administration. [cited 2024 Jun 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022352s026lbl.pdf

[26] van Durme CM, Wechalekar MD, Landewé RB, Pardo JP, Cyril S, Heijde Dvd, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2021; 12: CD010120.

[27] Roddy E, Clarkson K, Blagojevic-Bucknall M, Mehta R, Oppong R, Avery A, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 2020; 79: 276-84.

[28] Moon KW, Kim J, Kim JH, Song R, Lee EY, Song YW, et al. Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. Rheumatology (Oxford). 2011; 50: 2278-82.

[29] Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013; 30: 247-55.

[30] Möller B, Pruijm M, Adler S, Scherer A, Villiger PM, Finckh A, et al. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2015; 74: 718-23.

[31] Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? Am J Kidney Dis. 2020; 76: 546-57.

[32] Szeto C, Sugano K, Wang J, Fujimoto K, Whittle S, Modi GK, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020; 69: 617-29.

[33] Tang KS, Shah AD. Nonsteroidal anti-inflammatory drugs in end-stage kidney disease: dangerous or underutilized? Expert Opin Pharmacother. 2021; 22: 769-77.

[34] Janssens HJEM, Janssen M, Lisdonk EHvd, Riel PLCMv, Weel Cv. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008; 371: 1854-60.

[35] Rainer TH, Cheng CH, Janssens HJEM, Man CY, Tam LS, Choi YF, et al. Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. Ann Intern Med. 2016; 164: 464-71.

[36] Fernández C, Noguera R, González JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol. 1999; 26: 2285-6.

[37] Zhang Y, Yang H, Zhang J, Song L, Fan Y. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract. 2014; 68: 633-8.

[38] Xu Z, Zhang R, Zhang D, Yao J, Shi R, Tang Q, et al. Peptic ulcer hemorrhage combined with acute gout: analyses of treatment in 136 cases. Int J Clin Exp Med. 2015; 8: 6193-9.

[39] Harty T, O'Shaughnessy M, Harney S. Therapeutics in rheumatology and the kidney. Rheumatology (Oxford). 2023; 62: 1009-20.

[40] Oray M, Samra KA, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15: 457-65.

[41] Nisar MK. Crystallising the role of adrenocorticotrophic hormone in the management of acute gout: a review. Clin Exp Rheumatol. 2019; 37: 137-45.

[42] Ritter J, Kerr L, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994; 21: 696-9.

[43] Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine. 2013; 80: 291-4.

[44] Yang B, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003; 74: 85-94.

[45] Loustau C, Rosine N, Forien M, Ottaviani S, Juge P, Lioté F, et al. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine. 2018; 85: 755-60.

[46] Stamp LK, Frampton C, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, et al. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 2022; 4: e53-60.

[47] Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76: 47-56.

[48] Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64: 2529-36.

[49] Bathini L, Garg AX, Sontrop JM, Weir MA, Blake PG, Dixon SN, et al. Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study. Am J Kidney Dis. 2022; 80: 730-9.

[50] Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006; 33: 1646-50.

[51] Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017; 76: 1522-8.

[52] Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis. 2017; 76: 2065-70.

[53] Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, et al. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. Arthritis Res Ther. 2017; 19: 283.

[54] Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Res Ther. 2018; 20: 255.

[55] Wei J, Choi HK, Neogi T, Dalbeth N, Terkeltaub R, Stamp LK, et al. Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease: A Population-Based Cohort Study. Ann Intern Med. 2022; 175: 461-70.

[56] Guedes M, Zhao J, LaMoreaux B, Marder B, Gorlitsky B, Domingues V, et al.; DOPPS7 Country Investigators*. Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients. Kidney360. 2023; 4: 54-62.

[57] Yeo E, Palmer SC, Chapman PT, Frampton C, Stamp LK. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. Intern Med J. 2019; 49: 838-42.

[58] Doogue M, Wright D, Cross N, Irvine J, Chapman PT, Barclay M, et al. The pharmacokinetics of oxypurinol in patients treated with hemodialysis and allopurinol. Arthritis Rheum. 2016; 68: 4183-4.

[59] Arenas M, Soriano R, Andrés M, Pascual E. Serum Urate Levels of Hemodialyzed Renal Patients Revisited. J Clin Rheumatol. 2021; 27: e362-6.

[60] Wright DF, Doogue MP, Barclay ML, Chapman PT, Cross NB, Irvine JH, et al. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. Eur J Clin Pharmacol. 2017; 73: 71-8.

[61] Farquhar H, Vargas-Santos AB, Pisaniello HL, Fisher M, Hill C, Gaffo AL, et al. Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. Rheumatol Adv Pract. 2021; 5: rkaa073.

[62] Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, et al. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019; 71: 143-53.

[63] Kim S, Lee S, Kim J, Son C. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2020; 35: 998-1003.

[64] Kim Y, Ahn SM, Oh JS, Kim Y, Lee C, Yoo B, et al. Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study. Joint Bone Spine. 2024; 91: 105668.

[65] Jeong H, Park WY, Kim S, Dalbeth N, Son C. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies. Semin Arthritis Rheum. 2022; 56: 152073.

[66] Choi SY, Choi SW, Lee S, So MW, Oh JS, Lim D. Efficacy and tolerability of febuxostat in gout patients on dialysis. Intern Med J. 2021; 51: 348-54.

[67] BARTELS EC, MATOSSIAN GS. Gout: six-year follow-up on probenecid (benemid) therapy. Arthritis Rheum. 1959; 2: 193-202.

[68] Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013; 40: 872-6.

[69] Reinders MK, Roon ENv, Houtman PM, Brouwers JRBJ, Jansen TLTA. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007; 26: 1459-65.

[70] Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet. 2008; 47: 111-8.

[71] Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011; 38: 904-10.

[72] Case R, Wentworth B, Jester G. Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. BMJ Case Rep. 2018; 2018: bcr2017222845.

[73] Zürcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994; 9: 548-51.

[74] Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999; 5: 49-55.

[75] Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998; 57: 545-9.

[76] Yan F, Xue X, Lu J, Dalbeth N, Qi H, Yu Q, et al. Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. Arthritis Rheumatol. 2022; 74: 2015-23.

[77] Azevedo VF, Buiar PG, Giovanella LH, Severo CR, Carvalho M. Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol. 2014; 2014: 263720.

[78] Xue X, Sun M, Yan F, Dalbeth N, He Y, Li X, et al. Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia. Arthritis Care Res (Hoboken). 2024; 76: 703-11.

[79] PERSELLIN RH, SCHMID FR. The use of sulfinpyrazone in the treatment of gout. JAMA. 1961; 175: 971-5.

[80] Walls M, Goral S, Stone W. Acute renal failure due to sulfinpyrazone. Am J Med Sci. 1998; 315: 319-21.

[81] Yood RA, Ottery FD, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes. 2014; 7: 54.

[82] Baraf HSB, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014; 20: 427-32.

[83] Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014; 16: R60.

[84] Botson JK, Saag K, Peterson J, Obermeyer K, Xin Y, LaMoreaux B, et al. A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12-Month Findings. ACR Open Rheumatol. 2023; 5: 407-18.

[85] Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, et al. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis Rheumatol. 2023; 75: 293-304.

[86] Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, et al. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021; 73: 1523-32.

[87] Masri K, Winterling K, Lamoreaux B. Leflunomide co-therapy with pegloticase in uncontrolled gout. Annals of the Rheumatic Diseases. 2020; 79: 454.3-454.

[88] Bleyer AJ, Wright D, Alcorn H. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis. Clin Nephrol. 2015; 83: 286-92.